NO20031753L - Ny krystallinsk form av 6-hydroksy-3-(4-[2-piperidin-1- yl)etoksy]fenoksy)-2-(4-metoksyfenyl)benzo[b]tiofenhydroklorid - Google Patents

Ny krystallinsk form av 6-hydroksy-3-(4-[2-piperidin-1- yl)etoksy]fenoksy)-2-(4-metoksyfenyl)benzo[b]tiofenhydroklorid

Info

Publication number: NO20031753L
Authority: NO; Norway
Prior art keywords: piperidin; benzo; methoxyphenyl; phenoxy; ethoxy
Prior art date: 2000-10-20

Application number

NO20031753A

Other languages

English (en)

Norwegian (no)

Other versions

NO20031753D0 (no

Inventor

Wayne Douglas Luke

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-20

Filing date

2003-04-15

Publication date

2003-04-15

2003-04-15 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2003-04-15 Publication of NO20031753D0 publication Critical patent/NO20031753D0/no

2003-04-15 Publication of NO20031753L publication Critical patent/NO20031753L/no

Links

125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)

NO20031753A 2000-10-20 2003-04-15 Ny krystallinsk form av 6-hydroksy-3-(4-[2-piperidin-1- yl)etoksy]fenoksy)-2-(4-metoksyfenyl)benzo[b]tiofenhydroklorid NO20031753L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24225200P	2000-10-20	2000-10-20
PCT/US2001/027773 WO2002034741A2 (en)	2000-10-20	2001-10-18	A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE

Publications (2)

Publication Number	Publication Date
NO20031753D0 NO20031753D0 (no)	2003-04-15
NO20031753L true NO20031753L (no)	2003-04-15

Family

ID=22914051

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20031753A NO20031753L (no)	2000-10-20	2003-04-15	Ny krystallinsk form av 6-hydroksy-3-(4-[2-piperidin-1- yl)etoksy]fenoksy)-2-(4-metoksyfenyl)benzo[b]tiofenhydroklorid

Country Status (25)

Country	Link
US (1)	US20040014672A1 (es)
EP (1)	EP1328521A2 (es)
JP (1)	JP2004512333A (es)
KR (1)	KR20030037690A (es)
CN (1)	CN1268624C (es)
AR (1)	AR035355A1 (es)
AU (1)	AU2002214534A1 (es)
BR (1)	BR0114792A (es)
CA (1)	CA2426007A1 (es)
CZ (1)	CZ20031098A3 (es)
EA (1)	EA005116B1 (es)
EC (1)	ECSP034560A (es)
HR (1)	HRP20030296A2 (es)
HU (1)	HUP0301403A3 (es)
IL (1)	IL155487A0 (es)
MX (1)	MXPA03003432A (es)
MY (1)	MY125009A (es)
NO (1)	NO20031753L (es)
NZ (1)	NZ525364A (es)
PE (1)	PE20020588A1 (es)
PL (1)	PL360946A1 (es)
SK (1)	SK4902003A3 (es)
UA (1)	UA76124C2 (es)
WO (1)	WO2002034741A2 (es)
ZA (1)	ZA200303061B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2004283832B2 (en) *	2003-10-10	2011-04-07	Synthon B.V.	Solid-state montelukast
EP1773811B1 (en) *	2004-07-22	2010-09-08	Eli Lilly And Company	A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinecarbox amide hemisuccinate salt
BRPI0820811A2 (pt) *	2007-12-19	2018-03-27	Spectrum Pharmaceuticals Inc	formulação de sal estável de elsamitrucina
ATE536870T1 (de)	2009-09-25	2011-12-15	Iasomai Aktiebolag	N-acetyl-l-cystein zur behandlung von endometriose
PL236889B1 (pl) *	2017-10-03	2021-02-22	Univ Warszawski Medyczny	Nowa forma krystaliczna bezwodnego 17-β-estradiolu, sposób jej otrzymywania oraz kompozycja farmaceutyczna zawierająca nową formę krystaliczną bezwodnego 17-β-estradiolu i jej zastosowanie
MX2023011664A (es) *	2021-04-01	2023-10-11	Array Biopharma Inc	Forma cristalina de un inhibidor de shp2.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR003930A1 (es) *	1995-02-28	1998-09-30	Lilly Co Eli	Procedimiento para preparar compuestos de 2-fenil-3-fenoxi o feniltio-benzotiofeno y sales farmaceuticamente aceptables, compuestos intermediarios de aplicación exclusiva en dicho procedimiento y metodo para preparar los compuestos intermediarios mencionados
ZA982877B (en) *	1997-04-09	1999-10-04	Lilly Co Eli	Treatment of central nervous system disorders with selective estrogen receptor modulators.
AU6335600A (en) *	1999-07-29	2001-02-19	Eli Lilly And Company	A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride
ES2208384T3 (es) *	1999-07-29	2004-06-16	Eli Lilly And Company	Forma cristalina de clorhidrato de 6 hidroxi-3-(4-(2-(piperidin-1-il)-etoxi)-fenoxi)2--(4-metoxifenil)-benzo(b)tiofeno.

2001
- 2001-10-18 CZ CZ20031098A patent/CZ20031098A3/cs unknown
- 2001-10-18 NZ NZ525364A patent/NZ525364A/en unknown
- 2001-10-18 WO PCT/US2001/027773 patent/WO2002034741A2/en not_active Ceased
- 2001-10-18 JP JP2002537732A patent/JP2004512333A/ja active Pending
- 2001-10-18 CA CA002426007A patent/CA2426007A1/en not_active Abandoned
- 2001-10-18 MY MYPI20014862A patent/MY125009A/en unknown
- 2001-10-18 EP EP01983079A patent/EP1328521A2/en not_active Withdrawn
- 2001-10-18 SK SK490-2003A patent/SK4902003A3/sk not_active Application Discontinuation
- 2001-10-18 EA EA200300491A patent/EA005116B1/ru not_active IP Right Cessation
- 2001-10-18 UA UA2003043576A patent/UA76124C2/uk unknown
- 2001-10-18 AU AU2002214534A patent/AU2002214534A1/en not_active Abandoned
- 2001-10-18 IL IL15548701A patent/IL155487A0/xx unknown
- 2001-10-18 HR HR20030296A patent/HRP20030296A2/hr not_active Application Discontinuation
- 2001-10-18 AR ARP010104895A patent/AR035355A1/es unknown
- 2001-10-18 CN CNB018175813A patent/CN1268624C/zh not_active Expired - Fee Related
- 2001-10-18 US US10/399,523 patent/US20040014672A1/en not_active Abandoned
- 2001-10-18 BR BR0114792-7A patent/BR0114792A/pt not_active IP Right Cessation
- 2001-10-18 PE PE2001001040A patent/PE20020588A1/es not_active Application Discontinuation
- 2001-10-18 KR KR10-2003-7005501A patent/KR20030037690A/ko not_active Withdrawn
- 2001-10-18 PL PL01360946A patent/PL360946A1/xx unknown
- 2001-10-18 HU HU0301403A patent/HUP0301403A3/hu unknown
- 2001-10-18 MX MXPA03003432A patent/MXPA03003432A/es not_active Application Discontinuation
2003
- 2003-04-15 NO NO20031753A patent/NO20031753L/no not_active Application Discontinuation
- 2003-04-16 EC EC2003004560A patent/ECSP034560A/es unknown
- 2003-04-17 ZA ZA200303061A patent/ZA200303061B/en unknown

Also Published As

Publication number	Publication date
JP2004512333A (ja)	2004-04-22
NO20031753D0 (no)	2003-04-15
KR20030037690A (ko)	2003-05-14
EP1328521A2 (en)	2003-07-23
SK4902003A3 (en)	2003-10-07
AR035355A1 (es)	2004-05-12
EA200300491A1 (ru)	2003-08-28
PE20020588A1 (es)	2002-07-06
CN1268624C (zh)	2006-08-09
BR0114792A (pt)	2003-08-12
WO2002034741A3 (en)	2003-01-03
EA005116B1 (ru)	2004-10-28
HUP0301403A3 (en)	2009-05-28
HUP0301403A2 (hu)	2003-10-28
ECSP034560A (es)	2003-06-25
AU2002214534A1 (en)	2002-05-06
IL155487A0 (en)	2003-11-23
MY125009A (en)	2006-07-31
HK1061857A1 (en)	2004-10-08
CZ20031098A3 (cs)	2003-08-13
WO2002034741A2 (en)	2002-05-02
PL360946A1 (en)	2004-09-20
CA2426007A1 (en)	2002-05-02
MXPA03003432A (es)	2003-08-07
CN1469872A (zh)	2004-01-21
US20040014672A1 (en)	2004-01-22
ZA200303061B (en)	2004-07-19
NZ525364A (en)	2005-09-30
UA76124C2 (en)	2006-07-17
HRP20030296A2 (en)	2003-06-30

Legal Events

Date	Code	Title	Description
2006-05-29	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20003876L (no)	2001-01-30	En ny krystallinsk form av 6-hydroksy-3-(4-[2-(piperidin-1- yl)etoksy] fenoksy)-2-(4-metoksyfenyl)benzo[b]tiofen hydroklorid
NO20031753D0 (no)	2003-04-15	Ny krystallinsk form av 6-hydroksy-3-(4-[2-piperidin-1- yl)etoksy]fenoksy)-2-(4-metoksyfenyl)benzo[b]tiofenhydroklorid
NO20003879L (no)	2001-01-30	En ny krystallinsk form av 6-hydroksy-3-(4-[2-(piperidin-1- yl)etoksy] fenoksy)-2-(4-metoksyfenyl)benzo[b]tiofen hydroklorid
NO20025219L (no)	2002-10-31	Stabiliserte formuleringer av 6-hydroksy-3-(4-[2-(piperidin-1- yl)etoksy]fenoksy)-2-(4-metoksyfenyl)benzo[b]tiofen og salter derav
ZA200003837B (en)	2002-01-28	A novel chrystalline form of 6-hydroxy-3-(4-[2-)piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride.
ZA200003838B (en)	2002-01-28	A novel chrystalline form of 6-hydroxy-3-(4-[2-)piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride.
HK1059258A (en)	2004-06-25	A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
TJ20000620A (en)	2002-07-01	A novel crystalline form of 6-hydroxy-3-(4-Ä2-(piperidin-1-yl) ethoxy Ü phenoxy) - 2 - (4-methanoxyphenyl) benzo ÄbÜ thiophene hidrochloride
TJ398B (en)	2004-12-29	A novel crystalline form of 6-hydroxy -3-(4-Ä2-(piperidin-1-yl) ethoxyÜ-phenoxy) -2-(4-methoxyphenyl) benzo ÄbÜ thiophene hydrochloride.